Impact of Cecropin A and B on bladder cancer cells and fibroblasts

The four bladder cancer cell lines RT4, 647V, J82 and 486P as well as human (ZF07) and murine (3T6) fibroblasts were coincubated with increasing concentrations of up to 400 μg/ml Cecropin A and B. Cecropin A () and B () both demonstrate significant inhibitory activity on the viability of all four bladder cancer cell lines as measured by the WST-1 cell viability assay. In contrast, benign fibroblasts are less susceptible to Cecropin (p < 0,05). Additionally, Cecropin A () and B () both demonstrate significant inhibitory activity on the proliferation of all four bladder cancer cell lines as measured by the BrdU proliferation assay. In contrast, benign fibroblasts are not susceptible to Cecropin (p < 0,05). Cecropin A () and B () both exert significant cytotoxicity against all bladder cancer cell lines as measured by the LDH release assay. In contrast, benign fibroblasts are not susceptible to Cecropin-mediated cytolysis (p < 0,05). Experiments were performed in triplicate with results shown as mean ± standard deviation.<p><b>Copyright information:</b></p><p>Taken from "Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells"</p><p>http://www.biomedcentral.com/1471-2490/8/5</p><p>BMC Urology 2008;8():5-5.</p><p>Published online 3 Mar 2008</p><p>PMCID:PMC2276511.</p><p></p>